Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: An EORTC New Drug Development Group Study

European Journal of Cancer

Volumn 40, Issue 18, 2004, Pages 2748-2752

  Duffaud, F ^a   Borner, M ^b   Chollet, P ^c   Vermorken, J B ^d   Bloch, J ^e   Degardin, M ^f   Rolland, F ^g   Dittrich, C ^h   Baron, B ⁱ   Lacombe, D ⁱ   Fumoleau, P ^g  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITY OF BERN   (Switzerland)

^c CENTRE JEAN PERRIN   (France)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

ⁱ EORTC DATA CENTER   (Belgium)

Author keywords

Liposomal lurtotecan; Recurrent metastatic squamous cell carcinoma of the head and neck; Topoisomerase I inhibitor

Indexed keywords

LURTOTECAN;

ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPHAGIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; METASTASIS; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; STOMATITIS; TUMOR VOLUME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 9644281612     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.08.024     Document Type: Article

References (9)

1. X. Pivot, G. Poissonnet, and O. Dassonville An analysis of overall survival clinical prognostic factors for patients with locally recurrent or metastatic head and neck squamous cell carcinoma Oncology 61 2001 197 204
2. Emerson DL, McIntyre G, Luzzio ML et al. Preclinical antitumor activity of a novel water soluble camptothecin analog (GI147211C). In: 8th NCI-EORTC symposium on drugs. Cancer Ther 1994, 85
3. D.L. Emerson, A. Vuong, and M.S. Mc Intyre it In vivo efficacy of two new water-soluble camptothecin analogues in the human cancer xenograft model American Association for Cancer Research (AACR) 34 1993 119
4. D.L. Emerson, J.M. Besteman, and H.R. Brown In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues Cancer Res 55 1995 603 609
5. Emerson DL, Amirghahari N, Bendele R, et al. Enhanced in vivo antitumour efficacy of the liposome formulated topoisomerase I inhibitor lurtotecan. In: American Association for Cancer Research (AACR) meeting 1999, Abstr. 751. 1999, p. 40
6. K. Gelmon, H. Hirte, and B. Fisher A phase I study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers Invest New Drugs 22 2004 263 275
7. Eisenhauer EA, Verweij J, Rothenburg ML, et al. Phase I evaluation of liposomal topoisomerase I inhibitor, NX211, administered by three schedules to patients with advanced tumors. In: Proceedings of American Society of Clinical Oncology (ASCO) 2001, Abs. 409
8. P. Therasse, S.G. Arbuck, and E. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization in Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
9. W.J. Loos, D. Kehrere, and E. Brouwer Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography J Chromatogr B738 2000 155 163